Biodesign Israel
APPLY FOR THE OCTOBER 2020 PROGRAM
Registration is closed!
APPLY FOR THE OCTOBER 2020 PROGRAM
As for the 2020-21 course, the application deadline, interview dates and timeline for announcing decisions will remain the same. If necessary, we will host interviews and classes using a virtual format. Please follow our website for more information as it becomes available.
Program alumni pursue a wide variety of careers that include launching health technology start-ups, driving innovation inside major health technology companies and teaching innovation inside universities. To date, many interesting technologies have been invented and fifty health technology companies have been launched by the program’s graduates.
The Biodesign Innovation program begins on October 26th, 2020.
The clinical subspecialties chosen as the focus for the program in 2020-2021 are medical devices and digital health. We believe that by working on an area outside your specific field of expertise, you are more likely to question existing paradigms and recognize interesting opportunities. To jump-start the process, you will begin your training with several weeks of clinical immersion in the chosen subspecialty to observe first-hand how care is delivered in that space.
Here is a list of all our academic collaborations. If your specific faculty or institution does not appear on the list, please contact us.
Enrollment in Biodesign Israel is by application only. Final applicants will be invited to participate in an interview (online or in person).
Your application must include the following information:
The Biodesign Israel program is designed to provide up to 36 carefully selected students and professionals from the fields of medical science, engineering and business administration advanced training and mentoring in health technology innovation. In 2020-2021, the program will focus on innovation in the fields of medical devices and digital health, taking participants step by step through Stanford’s world-renowned Biodesign Innovation Process, to provide them with the tools to successfully implement their solutions in the global markets.
Participants will be divided into mastermind teams in which they will identify needs and develop solutions through ongoing cross-pollination for the duration of the program. Each team will be thoughtfully assembled to comprise two entrepreneurs from the field of medicine, two from the field of engineering and two from the field of business administration.
The program will be led by a highly trained and experienced faculty of four doctors, who are all graduates of the Stanford University Biodesign program. They will be joined by teaching assistants from relevant academic faculties and departments as well as experts from diverse disciplines, various hospital wards, HMOs and leading authorities from the Israeli tech industry, Silicon Valley and other leading global markets.
We are looking for smart, motivated, creative, and entrepreneurial participants with a commitment to improving healthcare, an interest in technology and a dedication to making a real-world impact.
The program is offered free of charge to up to 36 select undergraduate, graduate and postdoctoral-level students and professionals from the fields of medicine, engineering and business administration who work together in six multidisciplinary teams of six participants each. The program is recognized as academic accreditation for BA Engineering, BSc, MBA, M.Sc. Engineering students and medical interns. This is a fast-paced, demanding course and attendance is mandatory for the duration of the course (two semesters). Enrollment is by application only.
Biodesign Israel’s first course begins October 2020 and will take place over two semesters (one academic year), with sessions held on Mondays and Thursdays, 4 p.m. – 6 p.m. Some sessions will be led by Stanford Global Faculty members and other professionals from the US and global Biodesign partners. These sessions will be held at various times that will be scheduled and announced in advance.
July 1, 2020
During July
August 12-30, 2020
October 26, 2020
Based on the profound understanding that innovation must be designed to meet the users’ actual needs and challenges, a principle that is especially important in the medical field, the Biodesign Innovation Process involves the systematic identification and screening of needs from the ground up. This process, which Stanford has developed and refined over two decades, has been taught to thousands of participants at all levels in numerous countries around the world. Its application across a variety of fields within the medical landscape has led to exceptional results, enhancing the lives of millions around the globe.
This phase is first and foremost about finding important unmet health needs. By directly observing the full course of care, from diagnosis and treatment to recovery, as well as all the relevant players in the medical world, participants discover problems and opportunities. During this first-hand observation period, hundreds of needs are collected, initially with no judgment or prioritization. Then it’s time to filter the list with rigorous objectivity, taking into account everything from the different stakeholders affected by each need, to how much potential it has to improve care and/or save the system money, technological feasibility and business potential. This is an intense and iterative process, with progressively deeper dives into the needs that have the most potential. Ultimately, the trainees arrive at the two or three needs with the most promise for major impact on health and wellness.
This phase begins by brainstorming hundreds of potential solutions for each of the top needs. Then, the ideas are organized and objectively compared against key criteria for satisfying the needs. During this phase, participantas create rough prototypes in a rapid “think-build-rethink” sequence, so failures emerge early and iteration can lead to better solutions. They then filter the surviving solutions by researching everything from intellectual property issues and business models to reimbursement and regulatory pathways. In the end, the process produces several lead concepts perfectly suited to meet real needs, which are feasible from a business perspective and have a good chance of actually reaching and improving patient care.
This phase focuses on prototyping and testing the proposed technology in a quick and flexible way, while developing an approach to patenting, regulatory approval, reimbursement, charting market potential for the innovation and exploring sources of funding.
As mentioned, Stanford has been developing and refining this process for over two decades. An extremely broad number of participants from many countries around the world have undergone this training, at all levels of management and across a variety of medical fields. The results speak for themselves - this is an incredibly effective, systematic and proven process that is now being offered to entrepreneurs participating in the Biodesign Israel.